See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies
Cefiderocol for the treatment of infections due to metallo-beta-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies
Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor cinical candidate for treating COVID-19
Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor cinical candidate for treating COVID-19
Evidence for efficacy of cefiderocol against OXA-48-containing Isolates from the APEKS-NP and CREDIBLE-CR trials
Evidence for efficacy of cefiderocol against OXA-48-containing Isolates from the APEKS-NP and CREDIBLE-CR trials